ADmit Therapeutics SL
About
ADmit Therapeutics has developed the MAP-AD Test, the first prognostic blood test for Alzheimer's disease (AD) dementia. It is based on novel biomarkers discovered by our team and the IVDR has been developed in Barcelona. Using patented mitochondrial DNA biomarkers and AI, it predicts progression to AD in patients with first memory complaints, even before amyloid positivity. This facilitates early personalized interventions, optimizes clinical trial enrollment, and empowers patients and clinicians with crucial foresight. Our solution improves quality of life and offers significant economic savings.
GENOME RESEARCH
LIFE SCIENCE
E-HEALTH
BIOLOGY / BIOTECHNOLOGY
THERAPEUTIC AREA
MEDICINE
Representatives
CEO
ADmit Therapeutics SL